{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,28]],"date-time":"2026-07-28T20:02:26Z","timestamp":1785268946377,"version":"3.55.0"},"reference-count":32,"publisher":"Oxford University Press (OUP)","issue":"4","license":[{"start":{"date-parts":[[2025,9,27]],"date-time":"2025-09-27T00:00:00Z","timestamp":1758931200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0\/"}],"funder":[{"name":"Medical Oncology Research Fund"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2026,3,31]]},"abstract":"<jats:title>ABSTRACT<\/jats:title>\n                  <jats:sec>\n                    <jats:title>Background<\/jats:title>\n                    <jats:p>Acute kidney injury (AKI) is a known immune-related adverse event of cancer immune checkpoint inhibitor (ICI) therapy. Further population-based data on AKI incidence, risk factors and practice patterns post-ICI therapy are needed.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>We measured the cumulative incidence of AKI among advanced cancer patients while receiving ICI therapy and non-ICI systemic therapy in Ontario, Canada (2012\u201318). An increase in serum creatinine was used to define AKI and graded according to event severity. Time to event modeling was used to compare the risk of developing AKI, pre-disposing factors and survival outcomes.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>We studied 16\u2009425 patients with advanced cancer receiving either ICI or non-ICI systemic therapy. Among 4380 patients receiving ICI therapy, the overall crude 4-year incidence of AKI (any stage) was 29% and severe AKI (stage \u22652) was 7%. Characteristics associated with a higher risk of AKI included male sex, genitourinary (versus other) malignancy, the presence of hypertension, diabetes or chronic kidney disease, and prescription of a non-steroidal anti-inflammatory drug. The risk of experiencing AKI was significantly lower among patients treated with ICI versus non-ICI systemic therapy [adjusted hazards ratio (aHR) 0.80, 95% confidence interval (CI) 0.74\u20130.86, P-value &amp;lt;.0001]. Among the 587 patients who experienced an AKI and were both alive and discontinued ICI therapy within 30\u00a0days, 54 (9%) were re-challenged with ICI in the following 6\u00a0months and 24 (44%) had a recurrent AKI event. Patients who were re-challenged with ICI therapy had improved overall survival as compared with patients that received other non-ICI systemic therapy (aHR 0.38, 95% CI 0.22\u20130.67, P-value &amp;lt;.001).<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusion<\/jats:title>\n                    <jats:p>Our real-world study demonstrates a modest risk for severe AKI among cancer patients receiving ICI therapy, lower than with exposure to other systemic cancer therapies. Among patients who developed AKI and stopped ICI therapy, re-challenge was uncommon but may warrant consideration for select patients.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1093\/ndt\/gfaf191","type":"journal-article","created":{"date-parts":[[2025,9,13]],"date-time":"2025-09-13T11:40:13Z","timestamp":1757763613000},"page":"657-668","source":"Crossref","is-referenced-by-count":2,"title":["Practice patterns and outcomes in cancer patients developing immune checkpoint inhibitors\u2013related AKI"],"prefix":"10.1093","volume":"41","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-8865-0996","authenticated-orcid":false,"given":"Phillip S","family":"Blanchette","sequence":"first","affiliation":[{"name":"ICES Western, London Health Sciences Centre Research Institute, London Health Sciences Centre , London, Ontario ,","place":["Canada"]},{"name":"London Health Sciences Centre , London, Ontario ,","place":["Canada"]},{"name":"Division of Medical Oncology , Department of Oncology, Verspeeten Family Cancer Centre, Schulich School of Medicine and Dentistry, Western University, London, Ontario ,","place":["Canada"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jennifer","family":"Reid","sequence":"additional","affiliation":[{"name":"ICES Western, London Health Sciences Centre Research Institute, London Health Sciences Centre , London, Ontario ,","place":["Canada"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-6577-5067","authenticated-orcid":false,"given":"Lucie","family":"Richard","sequence":"additional","affiliation":[{"name":"ICES Western, London Health Sciences Centre Research Institute, London Health Sciences Centre , London, Ontario ,","place":["Canada"]},{"name":"Current affiliation: MAP Centre for Urban Health Solutions, Unity Health Toronto , Toronto, Ontario ,","place":["Canada"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Salimah Z","family":"Shariff","sequence":"additional","affiliation":[{"name":"ICES Western, London Health Sciences Centre Research Institute, London Health Sciences Centre , London, Ontario ,","place":["Canada"]},{"name":"Arthur Labatt Family School of Nursing, Western University , London ,","place":["Canada"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-9484-0224","authenticated-orcid":false,"given":"Jacques","family":"Raphael","sequence":"additional","affiliation":[{"name":"ICES Western, London Health Sciences Centre Research Institute, London Health Sciences Centre , London, Ontario ,","place":["Canada"]},{"name":"London Health Sciences Centre , London, Ontario ,","place":["Canada"]},{"name":"Division of Medical Oncology , Department of Oncology, Verspeeten Family Cancer Centre, Schulich School of Medicine and Dentistry, Western University, London, Ontario ,","place":["Canada"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Craig C","family":"Earle","sequence":"additional","affiliation":[{"name":"Sunnybrook Odette Cancer Centre, Sunnybrook Health Sciences Centre , Toronto, Ontario ,","place":["Canada"]},{"name":"University of Toronto Division of Medical Oncology Department of Medicine, , Ontario ,","place":["Canada"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Amit X","family":"Garg","sequence":"additional","affiliation":[{"name":"ICES Western, London Health Sciences Centre Research Institute, London Health Sciences Centre , London, Ontario ,","place":["Canada"]},{"name":"London Health Sciences Centre , London, Ontario ,","place":["Canada"]},{"name":"Division of Nephrology , Department of Medicine, Schulich School of Medicine and Dentistry, Western University, London, Ontario ,","place":["Canada"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-4340-5046","authenticated-orcid":false,"given":"Abhijat","family":"Kitchlu","sequence":"additional","affiliation":[{"name":"University Health Network , Toronto, Ontario ,","place":["Canada"]},{"name":"Division of Nephrology , Department of Medicine University of Toronto, Toronto, Ontario ,","place":["Canada"]}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"286","published-online":{"date-parts":[[2025,9,27]]},"reference":[{"key":"2026033111015240300_bib1","doi-asserted-by":"publisher","first-page":"675","DOI":"10.1093\/oncolo\/oyac085","article-title":"Utilization of immunotherapy in patients with cancer treated in routine care settings: a population-based study using health administrative data","volume":"27","author":"Raphael","year":"2022","journal-title":"Oncologist"},{"key":"2026033111015240300_bib2","doi-asserted-by":"publisher","first-page":"1490","DOI":"10.1056\/NEJMp1510079","article-title":"Releasing the brakes on cancer immunotherapy","volume":"373","author":"Ribas","year":"2015","journal-title":"N Engl J Med"},{"key":"2026033111015240300_bib3","doi-asserted-by":"crossref","first-page":"1165","DOI":"10.1056\/NEJMra1703481","article-title":"Adverse events associated with immune checkpoint blockade","volume":"378","author":"Postow","year":"2018","journal-title":"N Engl J Med"},{"key":"2026033111015240300_bib4","doi-asserted-by":"publisher","first-page":"4073","DOI":"10.1200\/JCO.21.01440","article-title":"Management of immune-related adverse events in patients treated with immune checkpoint inhibitor therapy: ASCO guideline update","volume":"39","author":"Schneider","year":"2021","journal-title":"J Clin Oncol"},{"key":"2026033111015240300_bib5","doi-asserted-by":"publisher","first-page":"iv119","DOI":"10.1093\/annonc\/mdx225","article-title":"Management of toxicities from immunotherapy: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up","volume":"28","author":"Haanen","year":"2017","journal-title":"Ann Oncol"},{"key":"2026033111015240300_bib6","doi-asserted-by":"publisher","first-page":"1077","DOI":"10.2215\/CJN.02340219","article-title":"AKI in patients receiving immune checkpoint inhibitors","volume":"14","author":"Perazella","year":"2019","journal-title":"Clin J Am Soc Nephrol"},{"key":"2026033111015240300_bib7","doi-asserted-by":"publisher","first-page":"1074","DOI":"10.1016\/j.xkme.2021.08.008","article-title":"Immune checkpoint inhibitors and kidney toxicity: advances in diagnosis and management","volume":"3","author":"Seethapathy","year":"2021","journal-title":"Kidney Med"},{"key":"2026033111015240300_bib8","first-page":"4607","article-title":"Ipilimumab-induced immune-related renal failure\u2014a case report","volume":"32","author":"Forde","year":"2012","journal-title":"Anticancer Res"},{"key":"2026033111015240300_bib9","doi-asserted-by":"publisher","first-page":"287","DOI":"10.1053\/j.ajkd.2016.02.057","article-title":"Association of acute interstitial nephritis with programmed cell death 1 inhibitor therapy in lung cancer patients","volume":"68","author":"Shirali","year":"2016","journal-title":"Am J Kidney Dis"},{"key":"2026033111015240300_bib10","doi-asserted-by":"publisher","first-page":"411","DOI":"10.1093\/ckj\/sfw024","article-title":"Severe acute interstitial nephritis after combination immune-checkpoint inhibitor therapy for metastatic melanoma","volume":"9","author":"Murakami","year":"2016","journal-title":"Clin Kidney J"},{"key":"2026033111015240300_bib11","doi-asserted-by":"publisher","first-page":"638","DOI":"10.1016\/j.kint.2016.04.008","article-title":"Clinicopathological features of acute kidney injury associated with immune checkpoint inhibitors","volume":"90","author":"Cortazar","year":"2016","journal-title":"Kidney Int"},{"key":"2026033111015240300_bib12","doi-asserted-by":"publisher","first-page":"108","DOI":"10.1093\/ndt\/gfy105","article-title":"Programmed cell death protein 1 inhibitor treatment is associated with acute kidney injury and hypocalcemia: meta-analysis","volume":"34","author":"Manohar","year":"2019","journal-title":"Nephrol Dial Transplant"},{"key":"2026033111015240300_bib13","doi-asserted-by":"publisher","first-page":"860","DOI":"10.1007\/s10637-020-01039-5","article-title":"Nephrotoxicity in patients with solid tumors treated with anti-PD-1\/PD-L1 monoclonal antibodies: a systematic review and meta-analysis","volume":"39","author":"Li","year":"2021","journal-title":"Invest New Drugs"},{"key":"2026033111015240300_bib14","doi-asserted-by":"publisher","first-page":"e000467","DOI":"10.1136\/jitc-2019-000467","article-title":"Acute kidney injury associated with immune checkpoint inhibitor therapy: incidence, risk factors and outcomes","volume":"8","author":"Meraz-Mu\u00f1oz","year":"2020","journal-title":"J Immunother Cancer"},{"key":"2026033111015240300_bib15","doi-asserted-by":"publisher","first-page":"435","DOI":"10.1681\/ASN.2019070676","article-title":"Clinical features and outcomes of immune checkpoint inhibitor-associated AKI: a multicenter study","volume":"31","author":"Cortazar","year":"2020","journal-title":"J Am Soc Nephrol"},{"key":"2026033111015240300_bib16","doi-asserted-by":"publisher","first-page":"e003467","DOI":"10.1136\/jitc-2021-003467","article-title":"Acute kidney injury in patients treated with immune checkpoint inhibitors","volume":"9","author":"Gupta","year":"2021","journal-title":"J Immunother Cancer"},{"key":"2026033111015240300_bib17","doi-asserted-by":"publisher","first-page":"1022","DOI":"10.1016\/j.ekir.2021.01.013","article-title":"Biomarkers, clinical features, and rechallenge for immune checkpoint inhibitor renal immune-related adverse events","volume":"6","author":"Isik","year":"2021","journal-title":"Kidney Int Rep"},{"key":"2026033111015240300_bib18","author":"ICES"},{"key":"2026033111015240300_bib19","doi-asserted-by":"publisher","first-page":"604","DOI":"10.7326\/0003-4819-150-9-200905050-00006","article-title":"A new equation to estimate glomerular filtration rate","volume":"150","author":"Levey","year":"2009","journal-title":"Ann Intern Med"},{"key":"2026033111015240300_bib20","first-page":"1","article-title":"KDIGO Clinical Practice Guideline for Acute Kidney Injury","volume":"2","author":"KDIGO Acute Kidney Injury Work Group","year":"2012","journal-title":"Kidney Int"},{"key":"2026033111015240300_bib21","doi-asserted-by":"publisher","first-page":"160","DOI":"10.1159\/000455014","article-title":"Adverse renal effects of immune checkpoint inhibitors: a narrative review","volume":"45","author":"Wanchoo","year":"2017","journal-title":"Am J Nephrol"},{"key":"2026033111015240300_bib22","doi-asserted-by":"publisher","first-page":"4373","DOI":"10.3390\/jcm11154373","article-title":"Renal toxicities in cancer patients receiving immune-checkpoint inhibitors: a meta-analysis","volume":"11","author":"Righini","year":"2022","journal-title":"J Clin Med"},{"key":"2026033111015240300_bib23","doi-asserted-by":"publisher","first-page":"1173952","DOI":"10.3389\/fimmu.2023.1173952","article-title":"Incidence and risk factors of acute kidney injury in cancer patients treated with immune checkpoint inhibitors: a systematic review and meta-analysis","volume":"14","author":"Liu","year":"2023","journal-title":"Front Immunol"},{"key":"2026033111015240300_bib24","doi-asserted-by":"publisher","first-page":"88","DOI":"10.1016\/j.ejim.2023.05.034","article-title":"Incidence, mortality, and risk factors of acute kidney injury after immune checkpoint inhibitors: systematic review and meta-analysis of real-world evidence","volume":"115","author":"Xie","year":"2023","journal-title":"Eur J Intern Med"},{"key":"2026033111015240300_bib25","doi-asserted-by":"publisher","first-page":"301","DOI":"10.1590\/2175-8239-jbn-2018-0021","article-title":"The relationship between proton pump inhibitors and renal disease","volume":"40","author":"Morschel","year":"2018","journal-title":"J Bras Nephrol"},{"key":"2026033111015240300_bib26","doi-asserted-by":"publisher","first-page":"2291","DOI":"10.3390\/ph3072291","article-title":"Nonsteroidal anti-inflammatory drugs and the kidney","volume":"3","author":"H\u00f6rl","year":"2010","journal-title":"Pharmaceuticals"},{"key":"2026033111015240300_bib27","doi-asserted-by":"publisher","first-page":"1343","DOI":"10.1007\/s10147-023-02385-z","article-title":"Acid suppressants reduce the therapeutic effect of immune checkpoint inhibitors and increase the risk of acute kidney injury: a meta-analysis","volume":"28","author":"Okamoto","year":"2023","journal-title":"Int J Clin Oncol"},{"key":"2026033111015240300_bib28","doi-asserted-by":"publisher","first-page":"439","DOI":"10.1159\/000538274","article-title":"Association of proton pump inhibitor use and immune checkpoint inhibitor-mediated acute kidney injury: a meta-analysis and a review of related outcomes","volume":"55","author":"Mohan","year":"2024","journal-title":"Am J Nephrol"},{"key":"2026033111015240300_bib29","doi-asserted-by":"publisher","first-page":"817","DOI":"10.1093\/ckj\/sfac194","article-title":"The association between acute kidney injury and outcomes in cancer patients receiving immune checkpoint inhibitor therapy: a systematic review and meta-analysis","volume":"16","author":"Kanbay","year":"2023","journal-title":"Clin Kidney J"},{"key":"2026033111015240300_bib30","doi-asserted-by":"crossref","first-page":"887","DOI":"10.1093\/ndt\/gfab034","article-title":"Acute kidney injury as a risk factor for mortality in oncological patients receiving checkpoint inhibitors","volume":"37","author":"Garcia-Carro","year":"2022","journal-title":"Nephrol Dial Transplant"},{"key":"2026033111015240300_bib31","doi-asserted-by":"publisher","first-page":"865","DOI":"10.1001\/jamaoncol.2020.0726","article-title":"Immune checkpoint inhibitor rechallenge after immune-related adverse events in patients with cancer","volume":"6","author":"Dolladille","year":"2020","journal-title":"JAMA Oncol"},{"key":"2026033111015240300_bib32","doi-asserted-by":"publisher","first-page":"884","DOI":"10.1093\/ckj\/sfaa027","article-title":"Acute tubulointerstitial nephritis induced by checkpoint inhibitors versus classical acute tubulointerstitial nephritis: are they the same disease?","volume":"14","author":"Draibe","year":"2021","journal-title":"Clin Kidney J"}],"container-title":["Nephrology Dialysis Transplantation"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/academic.oup.com\/ndt\/advance-article-pdf\/doi\/10.1093\/ndt\/gfaf191\/64356766\/gfaf191.pdf","content-type":"application\/pdf","content-version":"am","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/ndt\/article-pdf\/41\/4\/657\/64356766\/gfaf191.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/ndt\/article-pdf\/41\/4\/657\/64356766\/gfaf191.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,3,31]],"date-time":"2026-03-31T15:01:57Z","timestamp":1774969317000},"score":1,"resource":{"primary":{"URL":"https:\/\/academic.oup.com\/ndt\/article\/41\/4\/657\/8261486"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,9,27]]},"references-count":32,"journal-issue":{"issue":"4","published-online":{"date-parts":[[2025,9,27]]},"published-print":{"date-parts":[[2026,3,31]]}},"URL":"https:\/\/doi.org\/10.1093\/ndt\/gfaf191","relation":{},"ISSN":["0931-0509","1460-2385"],"issn-type":[{"value":"0931-0509","type":"print"},{"value":"1460-2385","type":"electronic"}],"subject":[],"published-other":{"date-parts":[[2026,4]]},"published":{"date-parts":[[2025,9,27]]}}}